Modified Acinetobacter baumannii Cells for Resistant Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Acinetobacter baumannii infections pose a significant health concern due to antibiotic resistance, with current treatments being ineffective against multi-drug and pan-drug resistant strains, leading to high morbidity and mortality rates, especially in hospital-acquired and community-acquired pneumonia cases.
Innovation Solution
The use of modified Acinetobacter baumannii transposon mutant cells, including mutations in genes such as lpsB, mffT, or GctA, which are administered as live or killed cells to stimulate an immune response against pathogenic bacteria, enhancing innate immunity and reducing bacterial virulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotic therapy is used to treat A. baumannii infections, then treatment of susceptible strains may be effective, but treatment fails against multi-drug and pan-drug resistant strains
Solution Approach 1:
The patent uses the patient's own immune system, which cannot distinguish between wild-type and mutant bacteria, to convert the presence of non-virulent mutant bacteria into a beneficial therapeutic effect. The mutant bacteria act as a biological weapon that exploits the pathogen's presence to stimulate protective immunity, turning the harmful infection into a healing process.
Solution Approach 2:
The non-virulent mutant bacteria serve as an intermediary between the pathogenic wild-type bacteria and the host immune system. These mutant cells mediate the interaction by stimulating immune responses that then act against the wild-type bacteria, providing a bridge that enables treatment without direct antibiotic intervention.
2Reliability
If virulent wild-type A. baumannii is present to cause infection, then immune system can be stimulated, but high bacterial burden causes severe disease and mortality
Solution Approach 1:
The patent applies local quality by creating bacteria with specific localized mutations that affect only virulence factors while leaving other bacterial functions intact. The mutations are targeted to specific genes (e.g., flagellar genes, type IV secretion system genes) to produce bacteria that retain immunogenicity but lack virulence, allowing differential properties within the same bacterial population.
Solution Approach 2:
The patent changes key parameters of bacterial behavior by mutating specific genes that control virulence attributes such as motility, adhesion, and toxin production. These parameter changes transform the bacteria from a harmful state to a beneficial state while maintaining their ability to stimulate immune responses.
3Reliability
If high doses of antibiotics are administered to overcome resistance, then bacterial load may be reduced, but toxicity and disruption of microbiome increase
Solution Approach 1:
The patent replaces the mechanical/chemical system of antibiotic action with a biological system based on immune recognition and response. Instead of using chemicals to kill bacteria directly, the therapy uses the patient's own immune system to selectively eliminate pathogenic bacteria, substituting a more selective and less toxic mechanism.
Solution Approach 2:
The therapy enables the patient's immune system to self-service by providing it with enhanced targets (mutant bacteria) that stimulate more effective immune responses. The body's own defenses do the work of clearing the infection, reducing the need for external toxic interventions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified cells significantly attenuate wild-type Acinetobacter baumannii virulence, leading to a substantial reduction in bacterial burdens and improved treatment outcomes, even surpassing the effectiveness of clinically relevant antibiotics in murine models, and demonstrate broad applicability against other Gram-negative pathogens.
Implementation Method 1
administered as live or killed cells to stimulate an immune response against pathogenic bacteria, enhancing innate immunity
Implementation Method 2
The modified cells significantly attenuate wild-type Acinetobacter baumannii virulence, leading to a substantial reduction in bacterial burdens
Data Source
AI summary
A cell, isolated nucleic acid, vector, isolated polypeptide, and method of treating a bacterial infection are provided. The cell includes a modified Acinetobacter baumannii cell having a mutation in an A. baumannii gene selected from a mutation that occurs when generating mutations in A. baumanni using transposon mutagenesis. The isolated nucleic acid includes a sequence expressing a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The vector includes the isolated nucleic acid. The isolated polypeptide includes a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The method of treating a bacterial infection includes administering to a subject an effective amount of an Acinetobacter baumannii composition including modified Acinetobacter baumannii cell.